Norway Pulmonary Arterial Hypertension Market Size & Outlook
The pulmonary arterial hypertension market in Norway is expected to reach a projected revenue of US$ 118.0 million by 2030. A compound annual growth rate of 4.6% is expected of Norway pulmonary arterial hypertension market from 2024 to 2030.
Revenue, 2023 (US$M)
$86.0
Forecast, 2030 (US$M)
$118.0
CAGR, 2024 - 2030
4.6%
Report Coverage
Norway
Norway pulmonary arterial hypertension market, 2018-2030 (US$M)
Related Markets
Norway pulmonary arterial hypertension market highlights
- The Norway pulmonary arterial hypertension market generated a revenue of USD 86.0 million in 2023 and is expected to reach USD 118.0 million by 2030.
- The Norway market is expected to grow at a CAGR of 4.6% from 2024 to 2030.
- In terms of segment, prostacyclin and prostacyclin analogs was the largest revenue generating drug class in 2023.
- SGC Stimulators is the most lucrative drug class segment registering the fastest growth during the forecast period.
Pulmonary arterial hypertension market data book summary
| Market revenue in 2023 | USD 86.0 million |
| Market revenue in 2030 | USD 118.0 million |
| Growth rate | 4.6% (CAGR from 2023 to 2030) |
| Largest segment | Prostacyclin and prostacyclin analogs |
| Fastest growing segment | SGC Stimulators |
| Historical data | 2018 - 2022 |
| Base year | 2023 |
| Forecast period | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Endothelin Receptor Antagonists (ERAs), PDE-5 Inhibitors, Prostacyclin and Prostacyclin Analogs, SGC Stimulators |
| Key market players worldwide | United Therapeutics Corp, Bayer AG, Gilead Sciences Inc, Johnson & Johnson, Viatris Inc, GlaxoSmithKline, Sandoz Group AG ADR, Lupin, Sun Pharmaceutical Industries, Teva Pharmaceutical Industries Ltd |
Other key industry trends
- In terms of revenue, Norway accounted for 1.2% of the global pulmonary arterial hypertension market in 2023.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Europe, Germany pulmonary arterial hypertension market is projected to lead the regional market in terms of revenue in 2030.
- Sweden is the fastest growing regional market in Europe and is projected to reach USD 133.7 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Pulmonary Arterial Hypertension Market Scope
Pulmonary arterial hypertension market segmentation & scope
Pulmonary Arterial Hypertension Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
Norway pulmonary arterial hypertension market size, by drug class, 2018-2030 (US$M)
Norway Pulmonary Arterial Hypertension Market Outlook Share, 2023 & 2030 (US$M)
Related regional statistics
No records
No related regions found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
